8-K: Allurion Secures $48 Million in Convertible Senior Secured Note Financing from RTW Investments

Allurion Technologies closes a $48 million convertible senior secured note financing with RTW Investments, simplifying its capital structure and extending its cash runway.

Summary

• Allurion Technologies has finalized a $48 million convertible senior secured note financing with RTW Investments.
• The funds will be used to fully repay Allurion's existing term loan with Fortress Credit Corp.
• This refinancing is expected to reduce Allurion's interest expenses and improve operational flexibility.
• The new notes have a 6% interest rate, a maturity date of April 16, 2031, and allow for interest payments to be made in-kind for the first three years.
• The amended terms of Allurion's existing Royalty Interest Financing Agreement with RTW, combined with the new notes, are expected to extend the company's cash runway.
• The notes are convertible into common stock at a 35% premium to the lower of the 30-day VWAP at signing and the price per share in the company's next equity offering.
• The notes may be redeemed by Allurion at its option under certain circumstances following the fourth anniversary of the date of issuance.

Sentiment

Score: 8

Explanation: The document is positive, highlighting a successful financing round, reduced interest expenses, and extended cash runway. The language used is optimistic and confident, suggesting a positive outlook for the company.

Positives

• The refinancing reduces Allurion's interest expenses.
• The new notes provide increased operational flexibility.
• The extended maturity of the notes provides long-term financial stability.
• The option to pay interest in-kind for the first three years improves near-term cash flow.
• The transaction strengthens Allurion's partnership with RTW Investments.

Risks

• The notes are convertible into common stock, which could dilute existing shareholders.
• The notes may be redeemed by Allurion at its option under certain circumstances following the fourth anniversary of the date of issuance, which could impact the return for noteholders.
• The company's ability to achieve its long-term goals is subject to various risks and uncertainties, including regulatory approvals, clinical trial results, and market competition.

Future Outlook

The company anticipates that this transaction will better position the business for the future and extend its expected cash runway in advance of the AUDACITY FDA trial read-out, which is anticipated by year-end.

Management Comments

• RTWs investment underscores our shared belief in the long-term potential of the Allurion Program, said Dr. Shantanu Gaur, Founder and CEO of Allurion.
• Our impressive clinical results and continued growth in procedural volume in our foreign markets give us confidence that Allurion will be a significant player in obesity management.
• We are pleased to strengthen our relationship with Allurion as it continues its mission to end obesity around the world. The Allurion Program is a proven weight-loss method, and we eagerly await the results of its U.S. FDA trial, said Roderick Wong, M.D., Managing Partner and Chief Investment Officer of RTW Investments, LP.

Industry Context

This announcement comes as the obesity management market is experiencing significant growth, with increasing demand for innovative and effective weight loss solutions. Allurion's focus on a procedure-less intragastric balloon and virtual care suite positions it to compete in this market.

Comparison to Industry Standards

• The 6% interest rate on the convertible notes is relatively low compared to typical rates for similar financings in the medical device industry, reflecting the confidence of RTW Investments in Allurion's potential.
• The option to pay interest in-kind for the first three years is a common feature in early-stage company financings, providing Allurion with flexibility to manage its cash flow.
• The 35% conversion premium is a standard feature in convertible note financings, providing noteholders with the potential for upside while also protecting existing shareholders from excessive dilution.
• The extension of the maturity date to April 2031 is a significant improvement over the previous term loan, providing Allurion with a longer runway to achieve its strategic goals.

Stakeholder Impact

• Shareholders may experience dilution if the notes are converted into common stock.
• The reduced interest expenses and extended cash runway should benefit the company's financial stability.
• The strengthened partnership with RTW Investments may provide additional support for the company's growth.
• The company's employees may benefit from the increased operational flexibility and long-term stability.

Next Steps

• Allurion will use the proceeds to repay its existing term loan.
• The company will continue to focus on the development and commercialization of the Allurion Program.
• The company will await the results of its AUDACITY FDA trial, which is anticipated by year-end.

Key Dates

Keywords

convertible notes, financing, RTW Investments, debt, refinancing, cash runway, Allurion, obesity, gastric balloon, FDA trial